The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | Cost-effectiveness of zanubrutinib vs rituximab-based therapy in Waldenström’s macroglobulinemia
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the cost-effectiveness of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström’s macroglobulinemia. Dr Castillo comments on data from the ASPEN trial (NCT03053440) and on the importance of analyzing cost-effectiveness. Touching on time to treatment failure, drug acquisition, cost of routine care and terminal care, Dr Castillo concludes that zanubrutinib appears to be cost-effective compared with ibrutinib for the treatment of Waldenström’s macroglobulinemia patients. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Jorge Castillo, MD, has received research funds and/or consulting fees from Abbvie, Beigene, Janssen, Pharmacyclics, Roche and TG Therapeutics.
